JERUSALEM, July 26, 2016 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP)
(http://www.oramed.com), a developer of oral drug delivery systems,
announced today the appointment of Dr. Roy
Eldor MD PhD to the newly created position of Chief Medical
Director.
"We are very pleased to welcome Dr. Eldor on board at this
pivotal time for Oramed as we head towards a Phase III trial for
our oral insulin capsule, ORMD-0801. Dr. Eldor will lead our
clinical development programs, with a specific near-term focus on
bringing ORMD-0801 through regulatory approval and to market,"
stated Oramed CEO, Nadav Kidron.
Dr. Roy Eldor is an
endocrinologist, internist and researcher with over twenty years of
clinical and scientific experience. He is currently Director of the
Diabetes Unit at the Institute of Endocrinology, Metabolism &
Hypertension, Tel-Aviv Sourasky Medical Center. Prior to that,
Dr. Eldor served as Principal Scientist at Merck Research
Laboratories, Clinical Research - Diabetes & Endocrinology,
Rahway, New Jersey. He has
previously served as a senior physician in internal medicine at the
Diabetes Unit in Hadassah Hebrew
University Hospital, Jerusalem,
Israel; the Diabetes Division at the University of Texas Health Science Center in
San Antonio, Texas (under the
guidance of Dr. R.A.
DeFronzo). Dr. Eldor is a recognized expert, with over
35 peer reviewed papers and book chapters and has been an invited
speaker to numerous international forums.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of
oral delivery solutions for drugs currently delivered via
injection. Established in 2006, Oramed's Protein Oral Delivery
(PODTM) technology is based on over 30 years of research
by top scientists at Jerusalem's
Hadassah Medical Center. Oramed is seeking to revolutionize the
treatment of diabetes through its proprietary flagship product, an
orally ingestible insulin capsule (ORMD-0801). The Company
completed multiple Phase II clinical trials under an
Investigational New Drug application with the U.S. Food and Drug
Administration. In addition, Oramed is developing an oral GLP-1
analog capsule (ORMD-0901).
For more information, the content of which is not part of this
press release, please visit http://www.oramed.com
Forward-looking statements: This press release contains
forward-looking statements. For example, we are using
forward-looking statements when we discuss our expected clinical
development programs and clinical trials or revolutionizing
the treatment of diabetes with our products. These forward-looking
statements are based on the current expectations of the management
of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements, including
the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent
protection for our product candidates; competition from other
pharmaceutical or biotechnology companies; and our ability to
obtain additional funding required to conduct our research,
development and commercialization activities. In addition, the
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements; delays
or obstacles in launching our clinical trials; changes in
legislation; inability to timely develop and introduce new
technologies, products and applications; lack of validation of our
technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the U.S. Securities and
Exchange Commission.
Company Contact
Oramed Pharmaceuticals
Estee Yaari
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: estee@oramed.com
SOURCE Oramed Pharmaceuticals Inc.